drugset / Trial / NCT03564119

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

NCT03564119 ↗

Phase 3 Completed 372 enrolled Sol-Gel Technologies, Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.

Timeline

Start
2018-06-21
Primary completion
2019-06-10
Completion
2019-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject S5G4T-1 Unknown 5 % Topical

Indications